Monoclonal antibodies therapy for Covid-19 - Experiences at a regional hospital.
Pannier, J.; Nass, N.; Behre, G.
Show abstract
Applying monoclonal antibodies against Covid-19 is a promising treatment option for avoiding severe outcomes. However, real life data, especially in regional hospitals are still scarce. We here report on our first results with this therapy in a retrospective, observational study. Indeed, compared to a risk-factor matched reference group, hospitalisation time was reduced but survival rate and kinetics of SARS-CoV-2 RT-PCR results remained apparently unaffected.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- SARS-CoV-2 viremia precedes an IL6 response in severe COVID-19 patients: results of a longitudinal prospective cohort 91%
- A retrospective study evaluating efficacy and safety of compassionate use of tocilizumab in 13 patients with severe-to-critically ill COVID-19: analysis of well-responding cases and rapidly-worsening cases after tocilizumab administration 91%
- SARS-CoV-2 antibody prevalence and symptoms in a local Austrian population 90%
Similar papers in this journal
- Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19, A double-blind, randomized placebo-controlled trial. 92%
- Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for Covid-19 patients in A Real-Life Setting: A Single Institute Analysis 91%
- A shorter symptom-onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis 91%
Similar papers in this journal
- EFFECTIVENESS OF CASIRIVIMAB-IMDEVIMAB AND SOTROVIMAB MONOCLONAL ANTIBODY TREATMENT AMONG HIGH-RISK PATIENTS WITH SARS-CoV-2 INFECTION: A REAL-WORLD EXPERIENCE 93%
- Patients at risk of pulmonary fibrosis Post Covid-19: Epidemiology, pulmonary sequelaes and humoral response 89%
- The SARS-CoV-2 cellular receptor ACE2 is expressed in oropharyngeal cells and is modulated in vitro by the bacterial lysate Lantigen B 89%
Similar papers in this journal
- Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial 92%
- Impact of vaccination on the presence and severity of symptoms of hospitalised patients with an infection by the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1) 91%
- An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results from the DisCoVeRy trial 91%
Similar papers in this journal
- Evaluation of the current therapeutic approaches for COVID-19: a meta-analysis 90%
- Echinacea purpurea for the Long-term Prevention of Viral Respiratory Tract Infections during COVID-19 Pandemic: A Randomized, Open, Controlled, Exploratory Clinical Study 90%
- Atovaquone for Treatment of COVID-19: A Prospective Randomized, Double-Blind, Placebo-Controlled Clinical Trial 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.